Ozempic and Wegovy: What the Science Shows [2026]

The cruelest irony of the GLP-1 revolution is this: the people with the most to gain from these medications — those with severe obesity, limited access to healthcare, and the highest metabolic disease burden — are frequently the ones least able to access them. A drug that's been called the most significant advance in obesity treatment in decades costs $1,000-1,300 per month at list price in the US, insurance coverage is inconsistent and often denied, and the global supply has struggled to keep up with explosive demand. Here is the honest breakdown of who can actually afford GLP-1 drugs and what the alternatives look like.

The Actual Cost Landscape

Semaglutide (Wegovy for obesity, Ozempic for diabetes) has a monthly list price of approximately $1,349 in the United States — making it one of the most expensive medications in wide use. Tirzepatide (Zepbound for obesity, Mounjaro for diabetes) runs similarly, around $1,060-1,200 per month. At these prices, the annual cost of treatment is $12,700-16,200 per patient per year, indefinitely, since weight regain occurs when medication stops.

The commercial insurance picture is mixed. Insurance coverage for obesity treatment has historically been poor in the US — the healthcare system has treated obesity as a lifestyle choice rather than a medical condition, and coverage has reflected that framing. The ACA requires insurers to cover preventive services but has no requirement to cover obesity medications. Many employer-sponsored plans have specifically excluded weight loss medications from their formularies. Medicare Part D (covering prescription drugs for seniors) was prohibited from covering weight loss medications until recently — the Treat and Reduce Obesity Act, passed in 2024, extended Medicare coverage to anti-obesity medications for the first time, representing a significant policy shift.

State Medicaid programs vary enormously. Some states have expanded Medicaid coverage to include GLP-1 medications for obesity; others have not. Federal Medicaid rules don't require coverage, leaving it to state discretion. The result: a person in Massachusetts with Medicaid may have coverage; the same person in Alabama may not. Geography determines access in ways that have nothing to do with medical need.

How Manufacturer Assistance Programs Work

Novo Nordisk (Wegovy/Ozempic) and Eli Lilly (Zepbound/Mounjaro) both offer patient assistance programs that can dramatically reduce out-of-pocket costs for eligible patients. The commercial insurance copay savings card programs can reduce monthly costs to $25-100 for commercially insured patients — the key word being "commercially insured." These savings cards don't work for Medicare or Medicaid patients, who are often the ones who need financial assistance most.

Patient assistance programs for uninsured or underinsured patients exist but have strict income eligibility requirements and often involve significant administrative burden. NovoCare (Novo Nordisk's program) and Lilly Cares (Eli Lilly's program) both offer free medication to qualifying low-income patients, but navigating the application process requires persistence and often the support of a healthcare provider with experience in the process.

The Compounding Pharmacy Option

During the period when FDA-designated semaglutide shortages existed, compounding pharmacies were legally permitted to produce their own versions of semaglutide. These compounded versions were available at dramatically lower prices ($200-400/month) through telehealth companies that offered prescriptions and compounded medication together. The FDA declared the semaglutide shortage resolved in early 2024, which triggered a complex legal and regulatory situation around compounded semaglutide that has played out through 2025-2026.

The current status of compounded semaglutide is legally contested. The FDA has moved to restrict compounding following the shortage resolution, and the compounding pharmacies and telehealth companies have challenged these restrictions through litigation. The practical situation for patients interested in compounded GLP-1s: the legal landscape is shifting, the safety profile of compounded versus branded medication is debated (compounded medications don't go through FDA approval), and anyone considering this option should be aware they're navigating a regulatory gray area.

The International Price Comparison That Should Embarrass the US

The same medication that costs $1,349/month in the US costs approximately $140/month in the UK, $90/month in Germany, and $80/month in Japan. The price differences reflect the different healthcare systems' negotiating power, price regulation approaches, and the specific way the US pharmaceutical market allows manufacturers to set prices for the private insurance market. The US price funds a disproportionate share of pharmaceutical companies' global profits, cross-subsidizing lower prices in other markets — a situation that is a feature of current US drug pricing policy, not a bug, from the manufacturers' perspective.

Medical tourism for GLP-1 medications — purchasing prescriptions abroad during travel — is a pattern that has emerged among American patients priced out of domestic access. Purchasing medication legally in another country for personal use is a gray area under US law; importing prescription medication across borders for personal use is technically illegal but rarely enforced for small personal-use quantities. This is not a recommendation; it's an accurate description of what some patients are doing to access medication they otherwise can't afford.

What Insurance Denial Looks Like (and How to Fight It)

Insurance denial of GLP-1 medications is common even when coverage technically exists. The most frequent denial reasons: the medication is deemed "not medically necessary" despite meeting FDA indications, prior authorization requirements that are burdensome enough to function as de facto denial, step therapy requirements (the insurer requires you to try and fail at other interventions first), or the medication being on a non-covered tier of the formulary.

The appeals process is worth pursuing. Internal appeals (to the insurance company) and external appeals (to an independent reviewer) overturn denials at meaningful rates — estimates suggest 30-50% of external appeals are decided in the patient's favor. The appeal process requires documentation: physician letters supporting medical necessity, documentation of BMI and obesity-related conditions, records of previous weight loss attempts. A physician who is familiar with GLP-1 appeals processes and willing to write a supporting letter is an asset in this process.

The Access Equity Problem

The populations with the highest rates of obesity and obesity-related metabolic disease in the US — lower-income communities, Black and Hispanic Americans, communities with limited healthcare access — are the same populations least likely to have commercial insurance that covers GLP-1 medications and most likely to face barriers to accessing the manufacturer assistance programs. The result is a situation where the most medically beneficial population has the most restricted access. This is a systemic healthcare equity problem that insurance coverage expansion, Medicaid policy change, and ultimately drug pricing reform are the levers to address — not individual strategies.

Important Limitations

The information here reflects general health evidence and is not a substitute for professional medical advice. Individual health situations vary significantly — what works for the average person in a clinical study may not be appropriate for your specific circumstances, medical history, or current medications. Consult a qualified healthcare provider before making significant changes to your health regimen, particularly for any existing conditions.

My take: If you have commercial insurance, check your formulary and use the manufacturer copay card if eligible — this can bring costs to $25-100/month. If denied, appeal with physician support documentation. If you're on Medicare, check whether your plan covers anti-obesity medications post-2024 policy change. The access inequity in GLP-1 availability is a systemic problem that deserves the same policy attention as the medications' clinical benefits have received.